New York Life Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

New York Life Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-295,670	Closed	-$899K	–	866
2024 Q4	$899K	Buy	295,670 +158,076	+115%	+$689K	0.01%	679
2024 Q3	$714K	Buy	+137,594	New	+$684K	0.01%	767

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York Life Investment Management's RVNC Position: Q1 2025 in Review

New York Life Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 295,670 shares — an estimated $899K sold.

New York Life Investment Management first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $899K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

New York Life Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
New York Life Investment Management sold 295,670 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $899K.
New York Life Investment Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
New York Life Investment Management's Revance Therapeutics, Inc. position peaked at $899K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on New York Life Investment Management's 13F filing for Q1 2025, filed 8 May 2025.